The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement

Simple item page
dc.contributor.authorWeiner, Michael W.
dc.contributor.authorVeitch, Dallas P.
dc.contributor.authorAisen, Paul S.
dc.contributor.authorBeckett, Laurel A.
dc.contributor.authorCairns, Nigel J.
dc.contributor.authorGreen, Robert C.
dc.contributor.authorHarvey, Danielle
dc.contributor.authorJack, Clifford R., Jr.
dc.contributor.authorJagust, William
dc.contributor.authorMorris, John C.
dc.contributor.authorPetersen, Ronald C.
dc.contributor.authorSalazar, Jennifer
dc.contributor.authorSaykin, Andrew J.
dc.contributor.authorShaw, Leslie M.
dc.contributor.authorToga, Arthur W.
dc.contributor.authorTrojanowski, John Q.
dc.contributor.departmentRadiology and Imaging Sciences, School of Medicineen_US
dc.date.accessioned2018-10-12T19:58:33Z
dc.date.available2018-10-12T19:58:33Z
dc.date.issued2017-05
dc.description.abstractINTRODUCTION: The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study. METHODS: ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition. RESULTS: Multimodal analyses will provide insight into AD pathophysiology and disease progression. DISCUSSION: ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationWeiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., … Trojanowski, J. Q. (2017). The Alzheimer’s Disease Neuroimaging Initiative 3: continued innovation for clinical trial improvement. Alzheimer’s & Dementia : The Journal of the Alzheimer’s Association, 13(5), 561–571. http://doi.org/10.1016/j.jalz.2016.10.006en_US
dc.identifier.urihttps://hdl.handle.net/1805/17540
dc.language.isoen_USen_US
dc.publisherElsevieren_US
dc.relation.isversionof10.1016/j.jalz.2016.10.006en_US
dc.relation.journalAlzheimer’s & Dementiaen_US
dc.rightsPublisher Policyen_US
dc.sourcePMCen_US
dc.subjectAlzheimer's diseaseen_US
dc.subjectAmyloid phenotypingen_US
dc.subjectBrain Health Registryen_US
dc.subjectCentiloid methoden_US
dc.subjectClinical trial biomarkersen_US
dc.subjectFunctional connectivityen_US
dc.subjectTau imagingen_US
dc.titleThe Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvementen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
nihms841893.pdf
Size:
438.6 KB
Format:
Adobe Portable Document Format
Description:
Main article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Department of Radiology and Imaging Sciences Works